June 22, 2024 06:00 AM EDT

Sarepta's big gene therapy expansion; Inside Iambic's AI cycle; Vertex, Lilly unveil new diabetes data; and more

Amber Tong

Senior Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarepta's big gene therapy expansion; Inside Iambic's AI cycle; Vertex, Lilly unveil new diabetes data; and more

Amber Tong

Senior Editor

Sign up to read this article for free.

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Sarep­ta's big gene ther­a­py ex­pan­sion; In­side Iambic's AI cy­cle; Ver­tex, Lil­ly un­veil new di­a­betes da­ta; and more

Amber Tong

Senior Editor

Sign up to read this article for free.

more like this

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

Sarepta's big gene therapy expansion; Inside Iambic's AI cycle; Vertex, Lilly unveil new diabetes data; and more

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B